{"protocolSection":{"identificationModule":{"nctId":"NCT01652716","orgStudyIdInfo":{"id":"BCB118"},"secondaryIdInfos":[{"id":"MB001-003","type":"OTHER","domain":"Bristol Myers Squibb"}],"organization":{"fullName":"AstraZeneca","class":"INDUSTRY"},"briefTitle":"Efficacy and Safety of Exenatide Once Weekly Suspension in Subjects With Type 2 Diabetes","officialTitle":"A Randomized, Open-Label, Long-Term, Parallel-Group, Comparator-Controlled, Multicenter Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Exenatide Twice Daily in Subjects With Type 2 Diabetes Mellitus","acronym":"DURATION-NEO-1"},"statusModule":{"statusVerifiedDate":"2018-05","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2013-01"},"primaryCompletionDateStruct":{"date":"2014-08","type":"ACTUAL"},"completionDateStruct":{"date":"2014-08","type":"ACTUAL"},"studyFirstSubmitDate":"2012-07-26","studyFirstSubmitQcDate":"2012-07-27","studyFirstPostDateStruct":{"date":"2012-07-30","type":"ESTIMATED"},"resultsFirstSubmitDate":"2015-08-04","resultsFirstSubmitQcDate":"2015-08-18","resultsFirstPostDateStruct":{"date":"2015-09-16","type":"ESTIMATED"},"lastUpdateSubmitDate":"2018-06-04","lastUpdatePostDateStruct":{"date":"2018-07-03","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"AstraZeneca","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"To compare the effect on glycemic control (HbA1c) of exenatide suspension administered once weekly to that achieved by exenatide administered twice daily for 28 weeks in subjects with type 2 diabetes mellitus.\n\nTo examine the long-term (52 weeks of treatment) safety and effect on glucose control of exenatide suspension administered once weekly in subjects with type 2 diabetes mellitus."},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":377,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Exenatide once weekly suspension","type":"EXPERIMENTAL","description":"Exenatide suspension 2 mg weekly subcutaneous injection","interventionNames":["Drug: Exenatide once weekly suspension"]},{"label":"Exenatide twice daily (BID)","type":"ACTIVE_COMPARATOR","description":"Exenatide 5 mcg BID for 4 weeks followed by 10 mcg BID for 24 weeks","interventionNames":["Drug: Exenatide twice daily"]}],"interventions":[{"type":"DRUG","name":"Exenatide once weekly suspension","description":"Exenatide suspension 2 mg weekly subcutaneous injection","armGroupLabels":["Exenatide once weekly suspension"]},{"type":"DRUG","name":"Exenatide twice daily","description":"5 mcg twice daily for 4 weeks followed by 10 mcg twice daily for 24 weeks","armGroupLabels":["Exenatide twice daily (BID)"],"otherNames":["Byetta"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Change in HbA1c (Glycosylated Hemoglobin) From Baseline to Week 28","description":"The primary objective of this study was to compare the effect on glycemic control (HbA1c) of exenatide suspension administered once weekly to that achieved by exenatide administered twice daily for 28 weeks in subjects with type 2 diabetes mellitus.","timeFrame":"Baseline to Week 28"}],"secondaryOutcomes":[{"measure":"Percentage of Subjects Achieving HbA1c <7% at Week 28","description":"Percentage of subjects achieving HbA1c \\<7% at Week 28/Study Termination","timeFrame":"Baseline to Week 28"},{"measure":"Change in Fasting Plasma Glucose Concentrations From Baseline to Week 28","description":"Change in fasting plasma glucose concentrations from baseline to Week 28/Study Termination","timeFrame":"Baseline to Week 28"},{"measure":"Change in Body Weight (kg) From Baseline to Week 28","description":"Change in body weight (kg) from baseline to Week 28/Study Termination.","timeFrame":"Baseline to Week 28"},{"measure":"Change in 2-hour Postprandial Glucose Concentrations From Baseline to Week 16","description":"Change in 2-hour postprandial glucose concentrations from baseline to Week 16.","timeFrame":"Baseline to Week 16"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* At least 18 years old\n* Diagnosed with type 2 diabetes mellitus\n* HbA1c 7.1 to 11%, inclusive, at screening\n* Fasting plasma glucose \\<280 mg/dL (15.5 mmol/L)\n* Body mass index (BMI) \\<=45 kg/m2, inclusive, at screening\n* Treated with diet and exercise or a stable regimen of metformin, sulfonylurea, pioglitazone or any 2 of these agents\n\nExclusion Criteria:\n\n* History of pancreatitis or triglycerides \\>=500 mg/dL\n* Medullary carcinoma or multiple endocrine neoplasia (MEN2) or a family history of either\n* Active cardiovascular disease\n* Presence of congestive heart failure\n* Liver disease\n* History of severe gastrointestinal diseases\n* Repeated severe hypoglycemia within the last 6 months\n* Any previous use of exenatide or other glucagon-like peptide-1 (GLP-1 ) analog\n* Dipeptidyl peptidase-4 (DPP-4) inhibitor use in the last 3 months","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Vice President Medical Research & Development, M.D.","affiliation":"Amylin Pharmaceuticals, LLC.","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Research Site","city":"Muscle Shoals","state":"Alabama","zip":"35662","country":"United States","geoPoint":{"lat":34.74481,"lon":-87.66753}},{"facility":"Research Site","city":"Mesa","state":"Arizona","zip":"85206","country":"United States","geoPoint":{"lat":33.42227,"lon":-111.82264}},{"facility":"Research Site","city":"Phoenix","state":"Arizona","zip":"85020","country":"United States","geoPoint":{"lat":33.44838,"lon":-112.07404}},{"facility":"Research Site","city":"Little Rock","state":"Arkansas","zip":"72205","country":"United States","geoPoint":{"lat":34.74648,"lon":-92.28959}},{"facility":"Research Site","city":"Escondido","state":"California","zip":"92026","country":"United States","geoPoint":{"lat":33.11921,"lon":-117.08642}},{"facility":"Research Site","city":"Garden Grove","state":"California","zip":"92844","country":"United States","geoPoint":{"lat":33.77391,"lon":-117.94145}},{"facility":"Research Site","city":"Lomita","state":"California","zip":"90717","country":"United States","geoPoint":{"lat":33.79224,"lon":-118.31507}},{"facility":"Research Site","city":"Los Angeles","state":"California","zip":"90015","country":"United States","geoPoint":{"lat":34.05223,"lon":-118.24368}},{"facility":"Research Site","city":"Santa Ana","state":"California","zip":"92705","country":"United States","geoPoint":{"lat":33.74557,"lon":-117.86783}},{"facility":"Research Site","city":"Spring Valley","state":"California","zip":"91978","country":"United States","geoPoint":{"lat":32.74477,"lon":-116.99892}},{"facility":"Research Site","city":"Walnut Creek","state":"California","zip":"94598","country":"United States","geoPoint":{"lat":37.90631,"lon":-122.06496}},{"facility":"Research Site","city":"Denver","state":"Colorado","zip":"80220","country":"United States","geoPoint":{"lat":39.73915,"lon":-104.9847}},{"facility":"Research Site","city":"Coral Gables","state":"Florida","zip":"33134","country":"United States","geoPoint":{"lat":25.72149,"lon":-80.26838}},{"facility":"Research Site","city":"DeLand","state":"Florida","zip":"32720","country":"United States","geoPoint":{"lat":29.02832,"lon":-81.30312}},{"facility":"Research Site","city":"Kissimmee","state":"Florida","zip":"34741","country":"United States","geoPoint":{"lat":28.30468,"lon":-81.41667}},{"facility":"Research Site","city":"Miami","state":"Florida","zip":"33156","country":"United States","geoPoint":{"lat":25.77427,"lon":-80.19366}},{"facility":"Research Site","city":"Orlando","state":"Florida","zip":"32806","country":"United States","geoPoint":{"lat":28.53834,"lon":-81.37924}},{"facility":"Research Site","city":"Oviedo","state":"Florida","zip":"32765","country":"United States","geoPoint":{"lat":28.67,"lon":-81.20812}},{"facility":"Research Site","city":"Palm Harbor","state":"Florida","zip":"34684","country":"United States","geoPoint":{"lat":28.07807,"lon":-82.76371}},{"facility":"Research Site","city":"Ponte Vedra","state":"Florida","zip":"32081","country":"United States","geoPoint":{"lat":30.22746,"lon":-81.38008}},{"facility":"Research Site","city":"Chicago","state":"Illinois","zip":"60607","country":"United States","geoPoint":{"lat":41.85003,"lon":-87.65005}},{"facility":"Research Site","city":"Chicago","state":"Illinois","zip":"60616","country":"United States","geoPoint":{"lat":41.85003,"lon":-87.65005}},{"facility":"Research Site","city":"Lexington","state":"Kentucky","zip":"40503","country":"United States","geoPoint":{"lat":37.98869,"lon":-84.47772}},{"facility":"Research Site","city":"Paducah","state":"Kentucky","zip":"42003","country":"United States","geoPoint":{"lat":37.08339,"lon":-88.60005}},{"facility":"Research Site","city":"Lake Charles","state":"Louisiana","zip":"70601","country":"United States","geoPoint":{"lat":30.21309,"lon":-93.2044}},{"facility":"Research Site","city":"Columbia","state":"Maryland","zip":"21045","country":"United States","geoPoint":{"lat":39.24038,"lon":-76.83942}},{"facility":"Research Site","city":"Elkridge","state":"Maryland","zip":"21075","country":"United States","geoPoint":{"lat":39.21261,"lon":-76.71358}},{"facility":"Research Site","city":"Hyattsville","state":"Maryland","zip":"20782","country":"United States","geoPoint":{"lat":38.95594,"lon":-76.94553}},{"facility":"Research Site","city":"New Bedford","state":"Massachusetts","zip":"02740","country":"United States","geoPoint":{"lat":41.63526,"lon":-70.92701}},{"facility":"Research Site","city":"Detroit","state":"Michigan","zip":"48202","country":"United States","geoPoint":{"lat":42.33143,"lon":-83.04575}},{"facility":"Research Site","city":"Troy","state":"Michigan","zip":"48098","country":"United States","geoPoint":{"lat":42.60559,"lon":-83.14993}},{"facility":"Research Site","city":"Edina","state":"Minnesota","zip":"55435","country":"United States","geoPoint":{"lat":44.88969,"lon":-93.34995}},{"facility":"Research Site","city":"Port Gibson","state":"Mississippi","zip":"39150","country":"United States","geoPoint":{"lat":31.96099,"lon":-90.98399}},{"facility":"Research Site","city":"St Louis","state":"Missouri","zip":"63128","country":"United States","geoPoint":{"lat":38.62727,"lon":-90.19789}},{"facility":"Research Site","city":"Butte","state":"Montana","zip":"59701","country":"United States","geoPoint":{"lat":46.00382,"lon":-112.53474}},{"facility":"Research Site","city":"Henderson","state":"Nevada","zip":"89052","country":"United States","geoPoint":{"lat":36.0397,"lon":-114.98194}},{"facility":"Research Site","city":"Endwell","state":"New York","zip":"13760","country":"United States","geoPoint":{"lat":42.11285,"lon":-76.02103}},{"facility":"Research Site","city":"New Windsor","state":"New York","zip":"12553","country":"United States","geoPoint":{"lat":41.47676,"lon":-74.02375}},{"facility":"Research Site","city":"Greensboro","state":"North Carolina","zip":"27408","country":"United States","geoPoint":{"lat":36.07264,"lon":-79.79198}},{"facility":"Research Site","city":"Cincinnati","state":"Ohio","zip":"45219","country":"United States","geoPoint":{"lat":39.12711,"lon":-84.51439}},{"facility":"Research Site","city":"Cincinnati","state":"Ohio","zip":"45227","country":"United States","geoPoint":{"lat":39.12711,"lon":-84.51439}},{"facility":"Research Site","city":"Columbus","state":"Ohio","zip":"43213","country":"United States","geoPoint":{"lat":39.96118,"lon":-82.99879}},{"facility":"Research Site","city":"Oklahoma City","state":"Oklahoma","zip":"73103","country":"United States","geoPoint":{"lat":35.46756,"lon":-97.51643}},{"facility":"Research Site","city":"Oklahoma City","state":"Oklahoma","zip":"73112","country":"United States","geoPoint":{"lat":35.46756,"lon":-97.51643}},{"facility":"Research Site","city":"Portland","state":"Oregon","zip":"97239","country":"United States","geoPoint":{"lat":45.52345,"lon":-122.67621}},{"facility":"Research Site","city":"Harleysville","state":"Pennsylvania","zip":"19438","country":"United States","geoPoint":{"lat":40.27955,"lon":-75.38712}},{"facility":"Research Site","city":"Charleston","state":"South Carolina","zip":"29407","country":"United States","geoPoint":{"lat":32.77632,"lon":-79.93275}},{"facility":"Research Site","city":"Mt. Pleasant","state":"South Carolina","zip":"29464","country":"United States","geoPoint":{"lat":32.79407,"lon":-79.86259}},{"facility":"Research Site","city":"Dallas","state":"Texas","zip":"75230","country":"United States","geoPoint":{"lat":32.78306,"lon":-96.80667}},{"facility":"Research Site","city":"Houston","state":"Texas","zip":"77062","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"Research Site","city":"San Antonio","state":"Texas","zip":"78205","country":"United States","geoPoint":{"lat":29.42412,"lon":-98.49363}},{"facility":"Research Site","city":"Murray","state":"Utah","zip":"84123","country":"United States","geoPoint":{"lat":40.66689,"lon":-111.88799}},{"facility":"Research Site","city":"Salt Lake City","state":"Utah","zip":"84107","country":"United States","geoPoint":{"lat":40.76078,"lon":-111.89105}},{"facility":"Research Site","city":"Manassas","state":"Virginia","zip":"20110","country":"United States","geoPoint":{"lat":38.75095,"lon":-77.47527}},{"facility":"Research Site","city":"Norfolk","state":"Virginia","zip":"23502","country":"United States","geoPoint":{"lat":36.84681,"lon":-76.28522}},{"facility":"Research Site","city":"Richmond","state":"Virginia","zip":"23294","country":"United States","geoPoint":{"lat":37.55376,"lon":-77.46026}},{"facility":"Research Site","city":"Olympia","state":"Washington","zip":"98502","country":"United States","geoPoint":{"lat":47.04491,"lon":-122.90169}},{"facility":"Research Site","city":"Spokane","state":"Washington","zip":"99202","country":"United States","geoPoint":{"lat":47.65966,"lon":-117.42908}}]},"referencesModule":{"references":[{"pmid":"33037036","type":"DERIVED","citation":"Wysham CH, Rosenstock J, Vetter ML, Wang H, Hardy E, Iqbal N. Further improvement in glycemic control after switching from exenatide two times per day to exenatide once-weekly autoinjected suspension in patients with type 2 diabetes: 52-week results from the DURATION-NEO-1 study. BMJ Open Diabetes Res Care. 2020 Oct;8(1):e000773. doi: 10.1136/bmjdrc-2019-000773."},{"pmid":"28685973","type":"DERIVED","citation":"Wysham CH, Rosenstock J, Vetter ML, Dong F, Ohman P, Iqbal N. Efficacy and tolerability of the new autoinjected suspension of exenatide once weekly versus exenatide twice daily in patients with type 2 diabetes. Diabetes Obes Metab. 2018 Jan;20(1):165-172. doi: 10.1111/dom.13056. Epub 2017 Aug 22."}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"Subjects were randomized across two treatment groups (exenatide once weekly and exenatide twice daily) in a ratio of 3:2 with randomization stratified by diabetes management method at screening, screening haemoglobin A1c (HbA1c) stratum and renal function.","groups":[{"id":"FG000","title":"Experimental: Exenatide Once Weekly (QWS) Suspension","description":"Exenatide suspension 2 mg weekly subcutaneous injection for 52 weeks (28 weeks plus an additional 24 weeks)"},{"id":"FG001","title":"Active Comparator: Exenatide Twice Daily (BID)","description":"Exenatide 5 mcg BID for 4 weeks followed by 10 mcg BID for 24 weeks followed by a switch to Exenatide QWS 2mg for at least 24 weeks"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"229"},{"groupId":"FG001","comment":"Two subjects in the exenatide BID group withdrew from the study before receiving study drug.","numSubjects":"148"}]},{"type":"Completed 28-week","achievements":[{"groupId":"FG000","numSubjects":"197"},{"groupId":"FG001","numSubjects":"118"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","comment":"\\* completed study","numSubjects":"173"},{"groupId":"FG001","comment":"\\* completed study","numSubjects":"102"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"56"},{"groupId":"FG001","numSubjects":"46"}]}],"dropWithdraws":[{"type":"Loss of glucose control","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Administrative","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"2"}]},{"type":"Investigator decision","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"4"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"12"},{"groupId":"FG001","numSubjects":"11"}]},{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"7"},{"groupId":"FG001","numSubjects":"10"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"33"},{"groupId":"FG001","numSubjects":"18"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"Modified Intent-to-Treat: Subjects who were randomized and received at least one dose of study drug","groups":[{"id":"BG000","title":"Experimental: Exenatide QWS Suspension","description":"Exenatide suspension 2 mg weekly subcutaneous injection 52 weeks (28 weeks plus an additional 24 weeks)"},{"id":"BG001","title":"Active Comparator: Exenatide BID","description":"Exenatide 5 mcg BID for 4 weeks followed by 10 mcg BID for 24 weeks followed by a switch to Exenatide QWS 2mg for at least 24 weeks"},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"229"},{"groupId":"BG001","value":"146"},{"groupId":"BG002","value":"375"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"55.6","spread":"9.98"},{"groupId":"BG001","value":"56.5","spread":"9.04"},{"groupId":"BG002","value":"56.0","spread":"9.62"}]}]}]},{"title":"Age, Customized","paramType":"NUMBER","unitOfMeasure":"Participants","classes":[{"title":"<65 years","categories":[{"measurements":[{"groupId":"BG000","value":"182"},{"groupId":"BG001","value":"118"},{"groupId":"BG002","value":"300"}]}]},{"title":">=65 years","categories":[{"measurements":[{"groupId":"BG000","value":"47"},{"groupId":"BG001","value":"28"},{"groupId":"BG002","value":"75"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"81"},{"groupId":"BG001","value":"54"},{"groupId":"BG002","value":"135"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"148"},{"groupId":"BG001","value":"92"},{"groupId":"BG002","value":"240"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"NUMBER","unitOfMeasure":"Participants","classes":[{"title":"Hispanic or Latino","categories":[{"measurements":[{"groupId":"BG000","value":"54"},{"groupId":"BG001","value":"34"},{"groupId":"BG002","value":"88"}]}]},{"title":"Not Hispanic or Latino","categories":[{"measurements":[{"groupId":"BG000","value":"174"},{"groupId":"BG001","value":"112"},{"groupId":"BG002","value":"286"}]}]},{"title":"Unknown","categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"NUMBER","unitOfMeasure":"Participants","classes":[{"title":"White","categories":[{"measurements":[{"groupId":"BG000","value":"168"},{"groupId":"BG001","value":"110"},{"groupId":"BG002","value":"278"}]}]},{"title":"Black or African American","categories":[{"measurements":[{"groupId":"BG000","value":"38"},{"groupId":"BG001","value":"23"},{"groupId":"BG002","value":"61"}]}]},{"title":"Asian","categories":[{"measurements":[{"groupId":"BG000","value":"17"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"25"}]}]},{"title":"Other","categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"5"}]}]},{"title":"American Indian or Alaska Native","categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"5"}]}]},{"title":"Native Hawaiian or Other Pacific Islander","categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}]}]}]},{"title":"Weight","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"lbs","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"214.52","spread":"49.788"},{"groupId":"BG001","value":"213.19","spread":"40.834"},{"groupId":"BG002","value":"214.00","spread":"46.445"}]}]}]},{"title":"Baseline HbA1c","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Percentage of total hemoglobin","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"8.47","spread":"1.047"},{"groupId":"BG001","value":"8.51","spread":"1.004"},{"groupId":"BG002","value":"8.48","spread":"1.029"}]}]}]},{"title":"HbA1c Stratum","paramType":"NUMBER","unitOfMeasure":"Number of subjects","classes":[{"title":"<9.0%","categories":[{"measurements":[{"groupId":"BG000","value":"159"},{"groupId":"BG001","value":"97"},{"groupId":"BG002","value":"256"}]}]},{"title":">=9.0%","categories":[{"measurements":[{"groupId":"BG000","value":"68"},{"groupId":"BG001","value":"49"},{"groupId":"BG002","value":"117"}]}]},{"title":"Not Recorded","categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"2"}]}]}]},{"title":"Fasting plasma glucose","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"mg/dL","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"180.92","spread":"44.538"},{"groupId":"BG001","value":"183.77","spread":"46.904"},{"groupId":"BG002","value":"182.03","spread":"45.437"}]}]}]},{"title":"Duration of diabetes","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"8.55","spread":"6.249"},{"groupId":"BG001","value":"8.47","spread":"5.961"},{"groupId":"BG002","value":"8.52","spread":"6.132"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Change in HbA1c (Glycosylated Hemoglobin) From Baseline to Week 28","description":"The primary objective of this study was to compare the effect on glycemic control (HbA1c) of exenatide suspension administered once weekly to that achieved by exenatide administered twice daily for 28 weeks in subjects with type 2 diabetes mellitus.","populationDescription":"Modified Intent-to-Treat: Subjects who were randomized and received at least one dose of study drug","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"Percentage of total hemoglobin","timeFrame":"Baseline to Week 28","groups":[{"id":"OG000","title":"Experimental: Exenatide QWS Suspension","description":"Exenatide suspension 2 mg weekly subcutaneous injection 52 weeks (28 weeks plus an additional 24 weeks)"},{"id":"OG001","title":"Active Comparator: Exenatide BID","description":"Exenatide 5 mcg BID for 4 weeks followed by 10 mcg BID for 24 weeks followed by a switch to Exenatide QWS 2mg for at least 24 weeks"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"229"},{"groupId":"OG001","value":"146"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.39","spread":"0.0930"},{"groupId":"OG001","value":"-1.02","spread":"0.1147"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0072","statisticalMethod":"Mixed model for repeated measure (MMRM)","statisticalComment":"Based on a repeated measures mixed model including fixed categorical effects of treatment","paramType":"LS Mean Difference","paramValue":"-0.37","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.63","ciUpperLimit":"-0.10","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.1349"}]},{"type":"SECONDARY","title":"Percentage of Subjects Achieving HbA1c <7% at Week 28","description":"Percentage of subjects achieving HbA1c \\<7% at Week 28/Study Termination","populationDescription":"Modified Intent-to-Treat: Subjects who were randomized and received at least one dose of study drug.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of subjects","timeFrame":"Baseline to Week 28","groups":[{"id":"OG000","title":"Experimental: Exenatide QWS Suspension","description":"Exenatide suspension 2 mg weekly subcutaneous injection 52 weeks (28 weeks plus an additional 24 weeks)"},{"id":"OG001","title":"Active Comparator: Exenatide BID","description":"Exenatide 5 mcg BID for 4 weeks followed by 10 mcg BID for 24 weeks followed by a switch to Exenatide QWS 2mg for at least 24 weeks"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"229"},{"groupId":"OG001","value":"146"}]}],"classes":[{"title":"Baseline Yes","categories":[{"measurements":[{"groupId":"OG000","value":"3.9"},{"groupId":"OG001","value":"1.4"}]}]},{"title":"Baseline No","categories":[{"measurements":[{"groupId":"OG000","value":"95.2"},{"groupId":"OG001","value":"98.6"}]}]},{"title":"Week 28 Yes","categories":[{"measurements":[{"groupId":"OG000","value":"49.3"},{"groupId":"OG001","value":"43.2"}]}]},{"title":"Week 28 No","categories":[{"measurements":[{"groupId":"OG000","value":"49.8"},{"groupId":"OG001","value":"56.8"}]}]},{"title":"Baseline missing","categories":[{"measurements":[{"groupId":"OG000","value":"0.9"},{"groupId":"OG001","value":"0"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.2247","statisticalMethod":"Cochran-Mantel-Haenszel"}]},{"type":"SECONDARY","title":"Change in Fasting Plasma Glucose Concentrations From Baseline to Week 28","description":"Change in fasting plasma glucose concentrations from baseline to Week 28/Study Termination","populationDescription":"Modified Intent-to-Treat: Subjects who were randomized and received at least one dose of study drug.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"mg/dL","timeFrame":"Baseline to Week 28","groups":[{"id":"OG000","title":"Experimental: Exenatide QWS Suspension","description":"Exenatide suspension 2 mg weekly subcutaneous injection 52 weeks (28 weeks plus an additional 24 weeks)"},{"id":"OG001","title":"Active Comparator: Exenatide BID","description":"Exenatide 5 mcg BID for 4 weeks followed by 10 mcg BID for 24 weeks followed by a switch to Exenatide QWS 2mg for at least 24 weeks"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"229"},{"groupId":"OG001","value":"146"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-32.7","spread":"3.906"},{"groupId":"OG001","value":"-22.5","spread":"4.917"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.1656","pValueComment":"Adjusted","statisticalMethod":"Cochran-Mantel-Haenszel","paramType":"LS Mean Difference","paramValue":"-10.2","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-21.7","ciUpperLimit":"1.3","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"5.841"}]},{"type":"SECONDARY","title":"Change in Body Weight (kg) From Baseline to Week 28","description":"Change in body weight (kg) from baseline to Week 28/Study Termination.","populationDescription":"Modified Intent-to-Treat: Subjects who were randomized and received at least one dose of study drug.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"kg","timeFrame":"Baseline to Week 28","groups":[{"id":"OG000","title":"Experimental: Exenatide QWS Suspension","description":"Exenatide suspension 2 mg weekly subcutaneous injection 52 weeks (28 weeks plus an additional 24 weeks)"},{"id":"OG001","title":"Active Comparator: Exenatide BID","description":"Exenatide 5 mcg BID for 4 weeks followed by 10 mcg BID for 24 weeks followed by a switch to Exenatide QWS 2mg for at least 24 weeks"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"229"},{"groupId":"OG001","value":"146"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.49","spread":"0.2842"},{"groupId":"OG001","value":"-1.89","spread":"0.3640"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.3744","statisticalMethod":"Cochran-Mantel-Haenszel","paramType":"LS Mean Difference","paramValue":"0.40","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.48","ciUpperLimit":"1.28","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.4497"}]},{"type":"SECONDARY","title":"Change in 2-hour Postprandial Glucose Concentrations From Baseline to Week 16","description":"Change in 2-hour postprandial glucose concentrations from baseline to Week 16.","populationDescription":"Meal Test Evaluable Subjects: Subjects who were randomized and received at least one dose of study drug and who participated in the meal test at Visit 3 and Visit 13, had adequate and reliable data for the postprandial data evaluation, and had adequate study medication exposure.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"mg/dL","timeFrame":"Baseline to Week 16","groups":[{"id":"OG000","title":"Experimental: Exenatide QWS Suspension","description":"Exenatide suspension 2 mg weekly subcutaneous injection 52 weeks (28 weeks plus an additional 24 weeks)"},{"id":"OG001","title":"Active Comparator: Exenatide BID","description":"Exenatide 5 mcg BID for 4 weeks followed by 10 mcg BID for 24 weeks followed by a switch to Exenatide QWS 2mg for at least 24 weeks"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"31"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-87.00","spread":"12.8374"},{"groupId":"OG001","value":"-113.74","spread":"14.8042"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0985","statisticalMethod":"Cochran-Mantel-Haenszel","paramType":"LS Mean Difference","paramValue":"26.74","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-5.16","ciUpperLimit":"58.64","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"15.8957"}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"up to 52 week data reported","eventGroups":[{"id":"EG000","title":"Experimental: Exenatide QWS Suspension","description":"Exenatide suspension 2 mg weekly subcutaneous injection 52 weeks (28 weeks plus an additional 24 weeks)","seriousNumAffected":12,"seriousNumAtRisk":229,"otherNumAffected":121,"otherNumAtRisk":229},{"id":"EG001","title":"Active Comparator: Exenatide BID","description":"Exenatide 5 mcg BID for 4 weeks followed by 10 mcg BID for 24 weeks followed by a switch to Exenatide QWS 2mg for at least 24 weeks","seriousNumAffected":17,"seriousNumAtRisk":146,"otherNumAffected":94,"otherNumAtRisk":146}],"seriousEvents":[{"term":"Localised Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":229},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":146}]},{"term":"Salmonellosis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":229},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":146}]},{"term":"Cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":229},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":146}]},{"term":"Septic Shock","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":229},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":146}]},{"term":"Myocardial Infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":229},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":146}]},{"term":"Pancreatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":229},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":146}]},{"term":"Diverticular Perforation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":229},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":146}]},{"term":"Syncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":229},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":146}]},{"term":"Toxic Encephalopathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":229},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":146}]},{"term":"Hidradentis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":229},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":146}]},{"term":"Drug Withdrawal Syndrome","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":229},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":146}]},{"term":"Lactic Acidosis","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":229},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":146}]},{"term":"Basal Cell Carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":229},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":146}]},{"term":"Uterine Leiomyoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":229},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":146}]},{"term":"Renal Failure Acute","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":229},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":146}]},{"term":"Acute Pulmonary Oedema","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":229},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":146}]},{"term":"Umbilical Hernia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":229},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":146}]},{"term":"Ascites","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":229},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":146}]},{"term":"Infectious Colitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":229},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":146}]},{"term":"Acute Myocardial Infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":229},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":146}]},{"term":"Atrial Fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":229},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":146}]},{"term":"Lower Limb Fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":229},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":146}]},{"term":"Osteoarthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":229},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":146}]},{"term":"Malignant Melanoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":229},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":146}]},{"term":"Hepatocellular Carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":229},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":146}]},{"term":"Carotid Artery Stenosis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":229},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":146}]},{"term":"Chest Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":229},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":146}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":229},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":146}]}],"otherEvents":[{"term":"Injection Site Nodule","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":37,"numAffected":36,"numAtRisk":229},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":146}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":30,"numAffected":22,"numAtRisk":229},{"groupId":"EG001","numEvents":38,"numAffected":33,"numAtRisk":146}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":16,"numAffected":14,"numAtRisk":229},{"groupId":"EG001","numEvents":10,"numAffected":9,"numAtRisk":146}]},{"term":"Upper Respiratory Tract Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":16,"numAffected":15,"numAtRisk":229},{"groupId":"EG001","numEvents":9,"numAffected":8,"numAtRisk":146}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":23,"numAffected":14,"numAtRisk":229},{"groupId":"EG001","numEvents":24,"numAffected":18,"numAtRisk":146}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":9,"numAtRisk":229},{"groupId":"EG001","numEvents":11,"numAffected":11,"numAtRisk":146}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":11,"numAtRisk":229},{"groupId":"EG001","numEvents":11,"numAffected":9,"numAtRisk":146}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"LTE60","restrictiveAgreement":true},"pointOfContact":{"title":"ClinicalTrialTransparency@astrazeneca.com","organization":"AstraZeneca","email":"ClinicalTrialTransparency@astrazeneca.com"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-10-09"},"conditionBrowseModule":{"meshes":[{"id":"D003924","term":"Diabetes Mellitus, Type 2"}],"ancestors":[{"id":"D003920","term":"Diabetes Mellitus"},{"id":"D044882","term":"Glucose Metabolism Disorders"},{"id":"D008659","term":"Metabolic Diseases"},{"id":"D009750","term":"Nutritional and Metabolic Diseases"},{"id":"D004700","term":"Endocrine System Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000077270","term":"Exenatide"}],"ancestors":[{"id":"D010455","term":"Peptides"},{"id":"D000602","term":"Amino Acids, Peptides, and Proteins"},{"id":"D014688","term":"Venoms"},{"id":"D045424","term":"Complex Mixtures"},{"id":"D014118","term":"Toxins, Biological"},{"id":"D001685","term":"Biological Factors"}]}},"hasResults":true}